Data Foundry

Drug recalls 2020

Olmesartan Medoxomil Tablets 20 mg — Class II drug recall D-0828-2020

Terminated recall by Ascend Laboratories LLC, reported 2020-02-12, distributed nationwide. cGMP Deviations; Olmesartan Medoximil Tablets 20 mg was released in error with alternate API source prior to f

Recall numberD-0828-2020
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmAscend Laboratories LLC, Parsippany, NJ, United States
Recall initiated2020-01-24
Classified2020-02-06
Reported by FDA2020-02-12
Terminated2021-10-29
DistributedNationwide (US)
Quantity192 bottles
Reason classescgmp
NDC67877-0445, 67877-0445-05, 67877-0445-10, 67877-0445-30, 67877-0445-90, 67877-0446, 67877-0446-05, 67877-0446-10, 67877-0446-30, 67877-0446-33, 67877-0446-38, 67877-0446-74, 67877-0446-84, 67877-0446-90, 67877-0447, 67877-0447-05, 67877-0447-10, 67877-0447-30, 67877-0447-90
Lot numbers19122552
Expiration dates2021-07-31

Product

Olmesartan Medoxomil Tablets 20 mg, Rx Only, 90 Tablets per Bottle, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013 INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC 67877-446-90.

Reason for recall

cGMP Deviations; Olmesartan Medoximil Tablets 20 mg was released in error with alternate API source prior to filing and approval of Prior Approval Supplement.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0828-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.